Key points are not available for this paper at this time.
Although omalizumab has shown success in treating chronic spontaneous urticaria (CSU) patients unresponsive to antihistamines, the exact mechanism of action and predictive markers of response remain unclear.
Chen et al. (Thu,) studied this question.